← 홈

고지혈증 · LDL · PCSK9

6개 · ADC 1048 · Antibody 5323 · CGT 2737 · 다음 갱신 D-14 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 6개
AntibodySHOTFDACuratedFDABiologicNovartisApproved

inclisiran (Leqvio, KJX839, ALN-PCS)

Hyperlipidemia, ASCVD, HeFH (LDL-C lowering) · PCSK9 (siRNA)

#PCSK9siRNA#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓50%임상시험 52상태 APPROVED
AntibodySHOTFDACuratedFDABiologicAmgenApproved

evolocumab (Repatha, AMG-145)

Hyperlipidemia, ASCVD risk reduction, HeFH, HoFH · PCSK9

#PCSK9#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓59%임상시험 51상태 APPROVED
AntibodySHOTFDACuratedFDABiologicSanofiApproved

alirocumab (Praluent, REGN727, SAR236553)

Hyperlipidemia, ASCVD, HeFH · PCSK9

#PCSK9#Antibody#Approved#FDA승인#바이오모아추천+5
효능 LDL-C ↓58%임상시험 45상태 APPROVED
AntibodyAmgenPhase 2

Evolocumab (Evolocumab)

Atherosclerotic Cardiovascular Disease; Symptomatic Atherosclerosis · Primary Hyperlipidemia and Mixed Dyslipi

#PrimaryHyperlipidemiaandMixedDys#Antibody#Phase2#인기#항체+5
효능 ORR 33.3%임상시험 52상태 ACTIVE
AntibodystaleSanofiPhase 2

Alirocumab (Alirocumab)

Hypercholesterolemia · Hypercholesterolemia

#Hypercholesterolemia#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleDaping Hospital and the Researc…Phase 2

PCSK9 Inhibitor (Tolecizumab, Tolecizumab (PCSK9 Inhibitor))

Colon Adenocarcinoma · Colon Adenocarcinoma

#ColonAdenocarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING